Exciting news in #breastcancer treatment: "The study... finds that patients who fall in the intermediate risk zone do as well with hormone therapy alone as with chemo plus hormone therapy after surgery." Original study: https://t.co/oBRfwSxBGg https://t
RT @RamalingamMD: Another feather on the hat for @eaonc. #ASC018 @WinshipAtEmory https://t.co/aLqIGFx1yW
The recurrence score based on the 21-gene breast cancer assay predicts chemotherapy benefit if it is high and a low risk of recurrence in the absence of chemotherapy if it is low 21遺伝子の乳癌再発値が高いと化学療法が有益、低いと化学療法なしでも再発し難い https://t.co/r1CfdkXv1M
RT @skathire: Using a gene-expression signature test to avoid unnecessary adjuvant chemo in BrCa! Pretty striking results, 10K women rando…
RT @NEJM: Original Article: Adjuvant Chemotherapy Guided by a 21-Gene Expression Assay in Breast Cancer (TAILORx) https://t.co/rQ4b15lb0s #…
RT @NEJM: Original Article: Adjuvant Chemotherapy Guided by a 21-Gene Expression Assay in Breast Cancer (TAILORx) https://t.co/rQ4b15lb0s #…
RT @NEJM: Original Article: Adjuvant Chemotherapy Guided by a 21-Gene Expression Assay in Breast Cancer (TAILORx) https://t.co/rQ4b15lb0s #…
Adjuvant Chemotherapy Guided by a 21-Gene Expression Assay in Breast Cancer | NEJM https://t.co/kXfmdSomks
RT @NEJM: Original Article: Adjuvant Chemotherapy Guided by a 21-Gene Expression Assay in Breast Cancer (TAILORx) https://t.co/rQ4b15lb0s #…
RT @NEJM: Original Article: Adjuvant Chemotherapy Guided by a 21-Gene Expression Assay in Breast Cancer (TAILORx) https://t.co/rQ4b15lb0s #…
Adjuvant Chemotherapy Guided by a 21-Gene Expression Assay in Breast Cancer | NEJM - https://t.co/QxV8sz3Tnq https://t.co/YT0MjX4zpD
RT @NEJM: Original Article: Adjuvant Chemotherapy Guided by a 21-Gene Expression Assay in Breast Cancer (TAILORx) https://t.co/rQ4b15lb0s #…
RT @NEJM: Original Article: Adjuvant Chemotherapy Guided by a 21-Gene Expression Assay in Breast Cancer (TAILORx) https://t.co/rQ4b15lb0s #…
This new study is getting alot of media attention! Adjuvant Chemotherapy Guided by a 21-Gene Expression Assay in Breast Cancer | NEJM https://t.co/e83n8EIz0y
RT @NEJM: Original Article: Adjuvant Chemotherapy Guided by a 21-Gene Expression Assay in Breast Cancer (TAILORx) https://t.co/rQ4b15lb0s #…
RT @elmodir: Adjuvant #Chemotherapy Guided by a 21-Gene Expression Assay in #BreastCancer : https://t.co/sMf6mcRtsS
RT @FutureDocsNow: Breaking news in breast cancer research #FutureDocsNow @NEJM https://t.co/C7tZYzaSYb
Exciting results from a large prospective trial @BreastImaging @RadiologyACR @AmericanCancer https://t.co/Mqi2eeh1Pu
Breaking news in breast cancer research #FutureDocsNow @NEJM https://t.co/C7tZYzaSYb
RT @NEJM: Original Article: Adjuvant Chemotherapy Guided by a 21-Gene Expression Assay in Breast Cancer (TAILORx) https://t.co/rQ4b15lb0s #…
Proud of my wife Claire on on the publication of TAILORx results in @NEJM today-immediate implications for vast numbers of breast cancer patients--#marriedabovemyself Adjuvant Chemotherapy Guided by a 21-Gene Expression Assay in Breast Cancer | NEJM https
RT @NEJM: Original Article: Adjuvant Chemotherapy Guided by a 21-Gene Expression Assay in Breast Cancer (TAILORx) https://t.co/rQ4b15lb0s #…
RT @skathire: Using a gene-expression signature test to avoid unnecessary adjuvant chemo in BrCa! Pretty striking results, 10K women rando…
RT @NEJM: Original Article: Adjuvant Chemotherapy Guided by a 21-Gene Expression Assay in Breast Cancer (TAILORx) https://t.co/rQ4b15lb0s #…
#TAILORx results are in! #bcsm #ASCO18 @NEJM https://t.co/mlhURJLnd3
#ASCO2018 results of #TAILORx trial : role of adjuvant endocrine therapy vs chemotherapy in mid range score @NEJM https://t.co/jUeDMrARzZ
RT @NEJM: Original Article: Adjuvant Chemotherapy Guided by a 21-Gene Expression Assay in Breast Cancer (TAILORx) https://t.co/rQ4b15lb0s #…
RT @NEJM: Original Article: Adjuvant Chemotherapy Guided by a 21-Gene Expression Assay in Breast Cancer (TAILORx) https://t.co/rQ4b15lb0s #…
RT @NEJM: Original Article: Adjuvant Chemotherapy Guided by a 21-Gene Expression Assay in Breast Cancer (TAILORx) https://t.co/rQ4b15lb0s #…
Tamoxifen +/- aromatase inhibition not inferior to Chemoendocrine therapy in ER positive/ HER neg breast cancer https://t.co/mP1ndGfOXe
RT @NEJM: Original Article: Adjuvant Chemotherapy Guided by a 21-Gene Expression Assay in Breast Cancer (TAILORx) https://t.co/rQ4b15lb0s #…
RT @NEJM: Original Article: Adjuvant Chemotherapy Guided by a 21-Gene Expression Assay in Breast Cancer (TAILORx) https://t.co/rQ4b15lb0s #…
RT @NEJM: Original Article: Adjuvant Chemotherapy Guided by a 21-Gene Expression Assay in Breast Cancer (TAILORx) https://t.co/rQ4b15lb0s #…
RT @NEJM: Original Article: Adjuvant Chemotherapy Guided by a 21-Gene Expression Assay in Breast Cancer (TAILORx) https://t.co/rQ4b15lb0s #…
RT @drtanws: One day soon hopefully for #bladdercancer #biomarker for selection of adjuvant therapy https://t.co/Y5krmULmgW
RT @NEJM: Original Article: Adjuvant Chemotherapy Guided by a 21-Gene Expression Assay in Breast Cancer (TAILORx) https://t.co/rQ4b15lb0s #…
RT @HenryKuerer: MORE info: Chemotherapy benefit for invasive disease–free survival varied with the combination of recurrence score and age…
RT @NEJM: Original Article: Adjuvant Chemotherapy Guided by a 21-Gene Expression Assay in Breast Cancer (TAILORx) https://t.co/rQ4b15lb0s #…
RT @NEJM: Original Article: Adjuvant Chemotherapy Guided by a 21-Gene Expression Assay in Breast Cancer (TAILORx) https://t.co/rQ4b15lb0s #…
RT @NEJM: Original Article: Adjuvant Chemotherapy Guided by a 21-Gene Expression Assay in Breast Cancer (TAILORx) https://t.co/rQ4b15lb0s #…
Original study in NEJM: Adjuvant endocrine & chemoendocrine therapy had similar efficacy in women with hormone-receptor +ve, HER2-ve, axillary node–ve breast cancer with a midrange 21-gene recurrence score, some benefit of chemo was found in some women
RT @NEJM: Original Article: Adjuvant Chemotherapy Guided by a 21-Gene Expression Assay in Breast Cancer (TAILORx) https://t.co/rQ4b15lb0s #…
RT @NEJM: Original Article: Adjuvant Chemotherapy Guided by a 21-Gene Expression Assay in Breast Cancer (TAILORx) https://t.co/rQ4b15lb0s #…
RT @NEJM: Original Article: Adjuvant Chemotherapy Guided by a 21-Gene Expression Assay in Breast Cancer (TAILORx) https://t.co/rQ4b15lb0s #…
RT @NEJM: Original Article: Adjuvant Chemotherapy Guided by a 21-Gene Expression Assay in Breast Cancer (TAILORx) https://t.co/rQ4b15lb0s #…
オンコタイプDX。年齢によりケモ内分泌の方がよい場合があるようですが、n数多すぎて解釈難しいですね。詳細は記事に書きます。 https://t.co/IC1nLmV8WB
One day soon hopefully for #bladdercancer #biomarker for selection of adjuvant therapy https://t.co/Y5krmULmgW
RT @MuinJKhoury: #TAILORx: And here are the highly anticipated results in today’s @NEJM https://t.co/yY58LdZY8g #ASC018
RT @GenomicHealth: .@NEJM publication on the long-awaited results of the #TAILORx study of #Oncotype DX, the largest ever breast cancer tre…
MORE info: There is some benefit of chemotherapy found in women 50 years of age or younger with a recurrence score of 16 to 25. #TailorX #breastcancer #ASCO18 https://t.co/pwvFmHUR6G
RT @NEJM: Original Article: Adjuvant Chemotherapy Guided by a 21-Gene Expression Assay in Breast Cancer (TAILORx) https://t.co/rQ4b15lb0s #…
RT @NEJM: Original Article: Adjuvant Chemotherapy Guided by a 21-Gene Expression Assay in Breast Cancer (TAILORx) https://t.co/rQ4b15lb0s #…
RT @NEJM: Original Article: Adjuvant Chemotherapy Guided by a 21-Gene Expression Assay in Breast Cancer (TAILORx) https://t.co/rQ4b15lb0s #…
RT @jdsteen1: Here's the NEJM paper on the TAILORx study of chemo in early breast cancer. #ReutersHealth #ASCO18 https://t.co/4ZdeKVEAJW
Based on Oncotype DX by Genomic Health: - Adjuvant Chemotherapy Guided by a 21-Gene Expression Assay in Breast Cancer | NEJM https://t.co/ljIpTIsWnY
RT @m0370: 朝になってNEJMを開いたら、#ASCO18 のプレナリーのうち乳癌TAILORxのarticleが掲載されていた。 /NEJM https://t.co/NXgo8EEtn7 https://t.co/Q67KPkchES
Here is the full publication of TAILORx, presented in plenary today #ASC018 @MayoCancerCare https://t.co/xeZ5Jq86kQ
RT @NEJM: Original Article: Adjuvant Chemotherapy Guided by a 21-Gene Expression Assay in Breast Cancer (TAILORx) https://t.co/rQ4b15lb0s #…
RT @NEJM: Original Article: Adjuvant Chemotherapy Guided by a 21-Gene Expression Assay in Breast Cancer (TAILORx) https://t.co/rQ4b15lb0s #…
Based on Oncotype DX by Genomic Health - Adjuvant Chemotherapy Guided by a 21-Gene Expression Assay in Breast Cancer | NEJM https://t.co/lVFBUMYgwS
RT @NEJM: Original Article: Adjuvant Chemotherapy Guided by a 21-Gene Expression Assay in Breast Cancer (TAILORx) https://t.co/rQ4b15lb0s #…
RT @Monthy_A: Adjuvant Chemotherapy Guided by a 21-Gene Expression Assay in Breast Cancer | NEJM https://t.co/6WKAoHoNWC
RT @roentgen66: Los resultados del estudio TAILORx presentados en #ASCO18 permitirán evitar quimioterapia en grupo de riesgo intermedio htt…
朝になってNEJMを開いたら、#ASCO18 のプレナリーのうち乳癌TAILORxのarticleが掲載されていた。 /NEJM https://t.co/NXgo8EEtn7 https://t.co/Q67KPkchES
RT @IOEssentials: Great news for estrogen receptor positive breast cancer patients who have tumors with an intermediate-risk Oncotype score…
RT @jesusanampa: momento histórico en el manejo de #cancer #MAMA Este estudio salvará a muchas mujeres de recibir quimioterapia en el futur…
RT @drrichardp: Important research on tests to make sure patients with breast cancer will actually benefit from chemotherapy ... it seems m…
RT @MuinJKhoury: #TAILORx: And here are the highly anticipated results in today’s @NEJM https://t.co/yY58LdZY8g #ASC018
RT @g_develasco: Real time @nejm @ASCO #ASCO18 and less chemo for #BreastCancer patients https://t.co/vlmFSjm7HX
RT @NEJM: Original Article: Adjuvant Chemotherapy Guided by a 21-Gene Expression Assay in Breast Cancer (TAILORx) https://t.co/rQ4b15lb0s #…
Practice-changing study just published! Adjuvant Chemotherapy Guided by a 21-Gene Expression Assay in Breast Cancer | NEJM https://t.co/4y5iLKWY4B
RT @CarmenLozanoEs: Original Article: Adjuvant Chemotherapy Guided by a 21-Gene Expression Assay in Breast Cancer (TAILORx) https://t.co/pB…
RT @NEJM: Original Article: Adjuvant Chemotherapy Guided by a 21-Gene Expression Assay in Breast Cancer (TAILORx) https://t.co/rQ4b15lb0s #…
RT @NEJM: Original Article: Adjuvant Chemotherapy Guided by a 21-Gene Expression Assay in Breast Cancer (TAILORx) https://t.co/rQ4b15lb0s #…
RT @NEJM: Original Article: Adjuvant Chemotherapy Guided by a 21-Gene Expression Assay in Breast Cancer (TAILORx) https://t.co/rQ4b15lb0s #…
RT @teamoncology: Here is the original article of TAILORx outcome. #asco18 #bcsm https://t.co/eXz3uFXXfw
RT @NEJM: Original Article: Adjuvant Chemotherapy Guided by a 21-Gene Expression Assay in Breast Cancer (TAILORx) https://t.co/rQ4b15lb0s #…
@DavidAngeles13 Agreed, but is this not the study? https://t.co/gAWzMxAlpo The hyperlink in the article is broken for some reason.
Here is the original article of TAILORx outcome. #asco18 #bcsm https://t.co/eXz3uFXXfw
Original Article: Adjuvant Chemotherapy Guided by a 21-Gene Expression Assay in Breast Cancer (TAILORx) https://t.co/pBCrNDZIUd #ASCO18 https://t.co/GRqnQiMGaW
RT @NEJM: Original Article: Adjuvant Chemotherapy Guided by a 21-Gene Expression Assay in Breast Cancer (TAILORx) https://t.co/rQ4b15lb0s #…
RT @RoxanaDaneshjou: In other avenues of genetics, ancestry can affect how predictive a test is across populations. I’m wondering because I…
RT @notahedge: #ASCO2018 #bcsm Rx for premenopausal women RS 18- 25 remains a grey zone. https://t.co/RubHiCOHgp
RT @skathire: Using a gene-expression signature test to avoid unnecessary adjuvant chemo in BrCa! Pretty striking results, 10K women rando…
RT @NEJM: Original Article: Adjuvant Chemotherapy Guided by a 21-Gene Expression Assay in Breast Cancer (TAILORx) https://t.co/rQ4b15lb0s #…
RT @NEJM: Original Article: Adjuvant Chemotherapy Guided by a 21-Gene Expression Assay in Breast Cancer (TAILORx) https://t.co/rQ4b15lb0s #…
RT @NEJM: Original Article: Adjuvant Chemotherapy Guided by a 21-Gene Expression Assay in Breast Cancer (TAILORx) https://t.co/rQ4b15lb0s #…
RT @NEJM: Original Article: Adjuvant Chemotherapy Guided by a 21-Gene Expression Assay in Breast Cancer (TAILORx) https://t.co/rQ4b15lb0s #…
MORE info: Chemotherapy benefit for invasive disease–free survival varied with the combination of recurrence score and age (P=0.004), with some benefit of chemotherapy found in women 50 years of age or younger with a recurrence score of 16 to 25. https://t
RT @drrichardp: Important research on tests to make sure patients with breast cancer will actually benefit from chemotherapy ... it seems m…
RT @perth_meso_dr: Simultaneous publication - #ASCO18 plenary https://t.co/PunA2E0nl5
Here's the NEJM paper on the TAILORx study of chemo in early breast cancer. #ReutersHealth #ASCO18 https://t.co/4ZdeKVEAJW
RT @g_develasco: Real time @nejm @ASCO #ASCO18 and less chemo for #BreastCancer patients https://t.co/vlmFSjm7HX
Simultaneous publication - #ASCO18 plenary https://t.co/PunA2E0nl5